Collexis' BiomedExperts Rapidly Expanding its User Base

Collexis Holdings Inc, (OTCBB: CLXS) a leading developer of high definition search and knowledge discovery software, announced that its premier professional scientific social networking site, Biomedexperts.com, has more than 30,000 registered users, enabling researchers across organizations and around the globe to collaborate more efficiently and effectively.

In April Collexis implemented the first phase of their marketing campaign and since that time BiomedExperts' user registrations have skyrocketed from 2,000 to more than 30,000. BiomedExperts.com is a collaborative agreement with Dell Healthcare and Life Sciences. Through this initiative, Dell is providing the hardware and continued marketing support for the site and Collexis is contributing knowledge discovery and text mining applications.

"The success of BiomedExperts.com is a testament to the role innovative technology can play in enabling researchers to collaborate and drive meaningful scientific discoveries," said James Coffin, Ph.D., vice president and general manager, Dell Health Care and Life Sciences. "The possibilities are tremendous when scientists of varying disciplines work together on a similar goal, and in this connected era bringing research communities together through technology can have real and significant impact on scientific discoveries and ultimately patient care."

Pre-populated with over 1.5 million Pub-Med-based expert profiles, BiomedExperts allows scientists and researchers to directly connect with and explore their own professional contacts, grow their networks and identify researchers with the expertise needed for future collaborations. Through user-friendly search interfaces, potential research collaborators can share data and collaborate with professionals from more than 1,800 organizations and institutions from 137 countries, totaling more than 21 million connections made through the site.

"It's exciting to see how this tool is paving the way for researchers to grow their professional networks and connect with professionals in the scientific research community," said Bill Kirkland, CEO of Collexis Holdings, Inc. "And now, with more than 30,000 registered users, we hope the collaborative opportunities will continue to increase rapidly, furthering our mission to provide scientists and researchers with the tools they need to help advance medical science, thereby improving the greater good."

To learn more about Collexis and how BiomedExperts is improving research capabilities, please visit www.collexis.comwww.collexis.com and www.biomedexperts.com.

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis’ proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis’ current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...